Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yaara Zisman-Ilani has a total of 345 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Identifying expanded adverse childhood experiences and examining their relationship with health outcomes: a systematic review protocol

    by Christine M Forke, Roy Wade, Jennifer Lege, Yaara Zisman-Ilani, Peter F Cronholm

  • Open Access

    Correction: Posttraumatic Stress Disorder Treatment Decision Aid: User-Centered Design Update Approach

    by Sadie E Larsen, Cybele Merrick, Yaara Zisman-Ilani, Karen B Eden, Shanna Treworgy, Jessica L Hamblen

  • Open Access

    Religiosity and Engagement in Early Intervention Programme for First‐Episode Psychosis

    by Alona Schneidman, David Roe, Yaara Zisman‐Ilani, Carmit‐Noa Shpigelman

    Background: While religious beliefs are known to affect help‐seeking pathways, little is known about how they shape engagement in first‐episode psychosis (FEP) care. The purpose of the present study is to explore how religious belief, religious identity and cultural norms shape engagement with FEP care. Methods: Semi‐structured interviews were conducted with 23 NAVIGATE participants in Israel. The sample comprised 11 Ultra‐Orthodox (UO) and 12 non‐observant (Non‐Obs) Jewish FEP participants. Thematic analysis was used to identify themes related to religious factors in FEP care engagement and the therapeutic alliance. Results: Two main themes emerged. The first focused on how faith contributed to participation in NAVIGATE by framing FEP care as God's will and viewing therapy as a spiritual experience. The second focused on trust issues, emphasising autonomy and collaborative decision‐making. Across both themes, the therapeutic relationship emerged as a critical independent source of NAVIGATE engagement. Conclusions: Findings indicate that religiosity shapes day‐to‐day engagement throughout FEP care, extending beyond initial help‐seeking. Implications are discussed with a focus on dialogue, psychoeducation and communication and on combining religious responsiveness with a strong therapeutic alliance.

  • Pharmacotherapeutic Decisions in Autism

    by Yaara Zisman-Ilani, Ron Walfisch, Jeremy Veenstra-VanderWeele, David S. Mandell

  • Open Access

    Correction: Posttraumatic Stress Disorder Treatment Decision Aid: User-Centered Design Update Approach (Preprint)

    by Sadie E Larsen, Cybele Merrick, Yaara Zisman-Ilani, Karen B Eden, Shanna Treworgy, Jessica L Hamblen

  • Open Access

    Shared decision making in pain care: a systematic review study protocol of decision aids

    by Courtney W Hess, Ashley McDonnell, Om Sahaym, Sahrish Masood, Aliyah Davis, Heather Smyth, Hannah Nguyen, Connie Wong, Ellen A Lipstein, Yaara Zisman-Ilani, et al.

    Introduction: Shared decision making (SDM) in healthcare is an ethical imperative and essential to patient-centred care. SDM is particularly useful when several preference-sensitive treatment options exist and in the setting of chronic conditions or longitudinal management. Chronic pain management embodies these characteristics, yet SDM often remains insufficient in this population. Decision aids are designed to facilitate SDM by helping patients and clinicians understand treatment options, clarify patient values, and guide collaborative decision processes. Despite their importance, the use of decision aids in pain management is inconsistent and their reported effectiveness has been variable. However, the current landscape of decision aids for pain management has not been described. This lack of understanding of what tools exist, how they are structured, what decisions they address and how they were developed makes it difficult to advance implementation efforts or identify meaningful gaps in available resources. As such, the purpose of this systematic review is to identify and characterise decision aids for pain management across the lifespan. Specifically, this review will describe the clinical decisions addressed, decision aid structures and delivery formats, development processes and outcomes used to evaluate the impact of existing decision aids. Methods and analysis: Electronic searches were performed in PubMed, CINAHL and Ovid Embase from inception through January 2026. Studies will be assessed for quality using the Mixed Methods Appraisal Tool. Data will be extracted and presented with the aim of describing the: (a) content and structures of pain-related decision aids, (b) development processes used to create existing pain-related decision aids and (c) outcome measures used to evaluate the impact of decision aids in clinical care. Ethics and dissemination: This review does not require ethics approval. Findings will be disseminated to clinicians, researchers and patients through journal publications, conference presentations and in collaboration with patient partners. PROSPERO registration number: CRD420251085288

  • Patient-Driven Care in Psychedelic Therapy

    by Yaara Zisman-Ilani, Rachel Yehuda

  • Open Access

    Posttraumatic Stress Disorder Treatment Decision Aid: User-Centered Design Update Approach

    by Sadie E Larsen, Cybele Merrick, Yaara Zisman-Ilani, Karen B Eden, Shanna Treworgy, Jessica L Hamblen

    Background: Posttraumatic stress disorder (PTSD) is associated with significant health and societal economic burdens, making treatment a priority. There are effective treatments, but there is no indication at this point which treatments will work best for which patients. Patient decision aids (DAs) are evidence-based tools designed to support patients and providers in weighing the benefits and risks of different treatment options and in making value-informed choices as one part of shared decision-making. The National Center for PTSD published an online PTSD Treatment DA in 2017. Objective: This paper outlines a collaborative process for significantly updating the PTSD Treatment DA in line with newer clinical practice guidelines and updated technological needs. Methods: The development and updating process was conducted by a small team in consultation with an expert panel and consumer input. User experience testing with people who screened positive for PTSD focused on the experience of completing specific core tasks such as comparing treatment options using the DA. Field testing included Veterans Administration patients and providers using the DA in clinical appointments to gather feedback about feasibility, satisfaction, acceptability, balance, fidelity, decisional conflict, and decisional self-efficacy. Results: Pilot field testing suggested that the PTSD Treatment DA was acceptable, satisfactory, balanced, feasible to implement, and associated with improvements in decisional conflict and in decisional self-efficacy in this small sample. Design decisions based on stakeholder feedback are described, including which treatments to include, what design format to use, how to assess preferences, and how to most effectively convey treatment effectiveness information. Conclusions: The revised PTSD Treatment Decision Aid is freely available online and is consistent with the International Patient Decision Aid Standards.


  • Open Access

    The Ethnopharmacological Use of Mescaline for Psychiatric Disorders: A Systematic Review

    by Jonathan Shaw, Aidan Yong, Jacky Lee, Justin Cheng, Anton Andricioaei, Jen-Yeu Wang, Yaara Zisman-Ilani, Robert Bota

    Mescaline, the primary bioactive alkaloid found in Peyote and San Pedro cactus, has been used in traditional medicine for centuries and is now attracting renewed interest for clinical applications. The purpose of this systematic review was to search the literature for studies reporting the use of mescaline to address the gap in our understanding of mescaline use and its impact. References were exported from PubMed, Scopus, Embase, and Cochrane. Included studies contained patient data pertaining to mescaline, primary sources for beliefs on the use of mescaline as traditional medicine, and a range of psychiatric conditions. Excluded studies included unpublished studies, animal studies, and studies without English full-texts available. Of 2770 imported references, 66 met the inclusion criteria, with only 10 being found suitable for analysis. Studies reported therapeutic effects such as improvements in depression scales, well-being, nicotine dependence, alcohol use, and obsessions. Bayesian analysis found that certain effects were frequently reported, such as hypertension, headache, nausea, and vomiting. The existing literature on mescaline is limited and of highly variable quality, preventing definitive conclusions regarding the prevalence of psychological and somatic effects from mescaline and mescaline-containing ethnobotanicals. Additional research is needed to determine the safety profile of mescaline. Given the prevalence of Peyote use in the Native American Church, the collaboration of the Native American Church and regional hospitals/poison centers is recommended to create a registry to allow for standardized and clinically applicable data collection on the effects of mescaline in prevalent populations.


  • Open Access

    Machine Learning–Based Audiovisual Phenotyping for Measuring Communication, Shared Decision-Making, and Trust

    by Shely Khaikin, Vineet Tiruvadi, Jeffrey Brooks, Alice Baird, Anne-Catherine Grela-Mpoko, Lindsey Hoffman, Jadyn Crossley, Menachem Leasy, Jaime Fineman, Margot Savoy, et al.

    Machine learning–based audiovisual phenotyping can reveal hidden discrepancies between patients’ self-reported experiences and nonverbal expressions, offering a promising tool for objectively assessing communication quality and advancing health equity.